Author

B. T. Seiler

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Research Focus:benchmarking· 1 Research Focus:drug response / drug discovery· 1 Organism:mouse· 1 Organism:plant (other)· 1 Organism:rat· 1

Frequent Co-Authors

M. Super· 3 shared D. E. Ingber· 2 shared D. J. Mooney· 2 shared E. J. Doherty· 2 shared F. Langellotto· 2 shared M. J. Cartwright· 2 shared A. G. Stafford· 1 shared A. L. M. Dinis· 1 shared

Activity by Year

2018-2020 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 38 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

M. Super

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

A rapidly adaptable biomaterial vaccine for SARS-CoV-2

F. Langellotto, B. T. Seiler, J. Yu, M. J. Cartwright, D. White, C. Yeager, M. Super, E. J. Doherty, D. H. Barouch, D. J. Mooney

This study develops a biomaterial vaccine using mesoporous silica rods to deliver SARS-CoV-2 antigens and adjuvants, showing rapid antibody responses and neutralizing activity.

bioRxiv · Jul 7, 2020 · PreprintImmunology

Modular biomaterials vaccine technology protects against multiple pathogens and septic shock

M. Super, E. J. Doherty, M. J. Cartwright, B. T. Seiler, D. A. White, F. Langellotto, A. G. Stafford, N. Dimitrakakis, M. Karkada, A. R. Graveline, C. L. Horgan, K. R. Lightbown, F. R. Urena, C. D. Yeager, S. A. Rifai, , D. J. Mooney

The paper introduces a modular vaccine technology (ciVAX) that protects against multiple pathogens and septic shock by using inactivated bacteria and biomaterial scaffolds.

bioRxiv · Feb 25, 2020 · PreprintImmunology

Broad spectrum capture of clinical pathogens using engineered Fc-Mannose-Binding Lectin (FcMBL) enhanced by antibiotic treatment

B. T. Seiler, M. Cartwright, A. L. M. Dinis, S. Duffy, P. Lombardo, D. Cartwright, E. H. Super, J. Lanzaro, K. Dugas, M. Super, D. E. Ingber

This study demonstrates that FcMBL binds to 86% of pathogen isolates and 90% of pathogen species, including bacteria, fungi, viruses, and parasites, and antibiotic treatment enhances its binding efficiency.

bioRxiv · Aug 8, 2018Immunology